[go: up one dir, main page]

AR069892A1 - Furina recombinante libre de proteinas sustancialmente animal y metodos para producirla. composicion. - Google Patents

Furina recombinante libre de proteinas sustancialmente animal y metodos para producirla. composicion.

Info

Publication number
AR069892A1
AR069892A1 ARP080105645A AR069892A1 AR 069892 A1 AR069892 A1 AR 069892A1 AR P080105645 A ARP080105645 A AR P080105645A AR 069892 A1 AR069892 A1 AR 069892A1
Authority
AR
Argentina
Prior art keywords
composition
free
methods
animal proteins
protein
Prior art date
Application number
Other languages
English (en)
Original Assignee
Baxter Healthcare Sa
Baxter Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40524590&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR069892(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Baxter Healthcare Sa, Baxter Int filed Critical Baxter Healthcare Sa
Publication of AR069892A1 publication Critical patent/AR069892A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/48Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424Serine endopeptidases (3.4.21)
    • C12N9/6454Dibasic site splicing serine proteases, e.g. kexin (3.4.21.61); furin (3.4.21.75) and other proprotein convertases
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Furina recombinante (rFurina) y métodos para producir la rFurina. Más específicamente, rFurina libre de proteínas sustancialmente animal y métodos para producir la rFurina libre de proteínas sustancialmente animales. Reivindicacion 1: Una composicion caracterizada porque comprende furina recombinante libre de proteínas sustancialmente animal. Reivindicacion 2: La composicion de la reivindicacion 1 caracterizada porque comprende furina recombinante a una actividad de por lo menos alrededor de 10000 U de furina/ml y CHO proteínas de células huésped a una concentracion menos de alrededor de 11 mg proteína/ml. Reivindicacion 14: Un método de uso de la composicion de la reivindicacion 1 caracterizado porque comprende el paso de contactar a pro-proteína con la composicion en condiciones para disociar un pro-péptido de la pro-proteína para formar una proteína madura. Reivindicacion 15: El método de la reivindicacion 14 caracterizado porque la proteína madura es Factor de von Willebrand. Reivindicacion 16: El método de la reivindicacion 14 caracterizado porque la proteína madura es Factor VIII.
ARP080105645 2007-12-31 2008-12-19 Furina recombinante libre de proteinas sustancialmente animal y metodos para producirla. composicion. AR069892A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US1815207P 2007-12-31 2007-12-31

Publications (1)

Publication Number Publication Date
AR069892A1 true AR069892A1 (es) 2010-02-24

Family

ID=40524590

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP080105645 AR069892A1 (es) 2007-12-31 2008-12-19 Furina recombinante libre de proteinas sustancialmente animal y metodos para producirla. composicion.
ARP180103625A AR113492A2 (es) 2007-12-31 2018-12-12 Furina recombinante libre de proteínas sustancialmente animal y métodos para producirla

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP180103625A AR113492A2 (es) 2007-12-31 2018-12-12 Furina recombinante libre de proteínas sustancialmente animal y métodos para producirla

Country Status (18)

Country Link
US (2) US20090181423A1 (es)
EP (2) EP3521422B1 (es)
JP (2) JP5806465B2 (es)
KR (1) KR101618144B1 (es)
CN (2) CN101910401A (es)
AR (2) AR069892A1 (es)
AU (1) AU2008346817B2 (es)
BR (1) BRPI0821467B8 (es)
CA (1) CA2710260C (es)
DK (1) DK2240578T3 (es)
ES (2) ES2897561T3 (es)
HU (1) HUE043863T2 (es)
MX (1) MX2010007344A (es)
NZ (1) NZ586411A (es)
PL (2) PL3521422T3 (es)
PT (1) PT2240578T (es)
SG (2) SG10201805749QA (es)
WO (1) WO2009088713A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5485873B2 (ja) * 2007-05-22 2014-05-07 バクスター・インターナショナル・インコーポレイテッド ヒトフューリンのための予備的な精製方法
WO2009088713A1 (en) 2007-12-31 2009-07-16 Baxter International Inc. Substantially animal protein-free recombinant furin and methods for producing same
US8241623B1 (en) 2009-02-09 2012-08-14 David Bermudes Protease sensitivity expression system
WO2012006594A1 (en) 2010-07-08 2012-01-12 Baxter International Inc. Method of producing recombinant adamts13 in cell culture
US20140051832A1 (en) * 2011-03-11 2014-02-20 Universidade De São Paulo - Usp Method for the production of recombinant human factor viii
SG195261A1 (en) * 2011-06-02 2013-12-30 Baxter Int Formulations of recombinant furin
AR102048A1 (es) * 2014-08-12 2017-02-01 Baxalta Inc Producción del factor x completamente procesado y funcional en un sistema de expresión de mamífero de secreción de furina
MX383857B (es) * 2014-12-22 2025-03-14 Genzyme Corp Métodos de cultivo de una célula de mamífero.
US11299533B2 (en) 2017-06-23 2022-04-12 Takeda Pharmaceutical Company Limited Purification of factor VIII subspecies

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1815207A (en) 1929-01-18 1931-07-21 John H Moffat Vehicle parking and locking device
NL9000917A (nl) 1989-10-25 1991-05-16 Holland Biotechnology Farmaceutisch preparaat met endoproteolytische activiteit; werkwijze voor endoproteolytische processing van (precursor) eiwitten en voor de (micro) biologische bereiding van eiwitten.
DK0574402T3 (da) 1990-11-26 1998-05-18 Chiron Corp Ekspression af PACE i værtsceller og fremgangsmåder til anvendelse deraf
US5604201A (en) * 1993-01-08 1997-02-18 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University, A Non-Profit Organization Methods and reagents for inhibiting furin endoprotease
AT404838B (de) * 1995-11-24 1999-03-25 Immuno Ag Herstellung von proteinen aus pro-proteinen durch fusionsproteine abgeleitet von furin oder furinanalogen
WO1998015614A1 (en) 1996-10-10 1998-04-16 Life Technologies, Inc. Animal cell culture media comprising plant-derived nutrients
AT407750B (de) 1999-02-19 2001-05-25 Immuno Ag Verfahren zur herstellung einer vwf-präparation
US6596526B1 (en) * 2000-06-09 2003-07-22 Baxter Aktiengesellschaft Furin polypeptides with improved characteristics
SE0103084D0 (sv) * 2001-09-14 2001-09-14 Amersham Pharm Biotech Ab Generation of ion exchange media
US20030091976A1 (en) * 2001-11-14 2003-05-15 Ciphergen Biosystems, Inc. Methods for monitoring polypeptide production and purification using surface enhanced laser desorption/ionization mass spectrometry
EP1520008B1 (en) * 2002-07-09 2012-09-05 Baxter International Inc. Animal protein free media for cultivation of cells
US7750129B2 (en) * 2004-02-27 2010-07-06 Ge Healthcare Bio-Sciences Ab Process for the purification of antibodies
PT1974014T (pt) * 2006-01-04 2017-05-26 Baxalta Inc Meios de cultura celulares livres de oligopeptídeos
JP5485873B2 (ja) * 2007-05-22 2014-05-07 バクスター・インターナショナル・インコーポレイテッド ヒトフューリンのための予備的な精製方法
WO2009088713A1 (en) 2007-12-31 2009-07-16 Baxter International Inc. Substantially animal protein-free recombinant furin and methods for producing same
US9718255B2 (en) 2011-11-03 2017-08-01 Barson Composites Corporation Corrosion-resistant diffusion coatings

Also Published As

Publication number Publication date
CN110066782B (zh) 2024-04-16
NZ586411A (en) 2012-06-29
US9127264B2 (en) 2015-09-08
EP3521422A1 (en) 2019-08-07
ES2897561T3 (es) 2022-03-01
CN101910401A (zh) 2010-12-08
SG10201805749QA (en) 2018-08-30
EP3521422B1 (en) 2021-10-06
AU2008346817A1 (en) 2009-07-16
JP2011507550A (ja) 2011-03-10
KR20100114057A (ko) 2010-10-22
AR113492A2 (es) 2020-05-06
WO2009088713A1 (en) 2009-07-16
BRPI0821467B8 (pt) 2021-05-25
DK2240578T3 (da) 2019-06-17
JP5806465B2 (ja) 2015-11-10
JP2015154790A (ja) 2015-08-27
EP2240578B1 (en) 2019-03-20
CA2710260C (en) 2023-07-11
PL2240578T3 (pl) 2019-09-30
KR101618144B1 (ko) 2016-05-17
BRPI0821467B1 (pt) 2019-10-15
US20110076719A1 (en) 2011-03-31
AU2008346817B2 (en) 2014-07-24
CA2710260A1 (en) 2009-07-16
ES2735173T3 (es) 2019-12-16
US20090181423A1 (en) 2009-07-16
EP2240578A1 (en) 2010-10-20
CN110066782A (zh) 2019-07-30
SG192471A1 (en) 2013-08-30
PL3521422T3 (pl) 2021-12-20
HUE043863T2 (hu) 2019-09-30
BRPI0821467A2 (pt) 2014-10-14
PT2240578T (pt) 2019-06-19
MX2010007344A (es) 2010-11-09

Similar Documents

Publication Publication Date Title
AR069892A1 (es) Furina recombinante libre de proteinas sustancialmente animal y metodos para producirla. composicion.
AR043826A1 (es) Formulaciones de proteinas y anticuerpos de alta concentracion
KR900700116A (ko) 뼈-유도 단백질
EA200001023A1 (ru) Специфическое в отношении fapa-(протеин альфа активации фибробласта) антитело с повышенной продуктивностью
ATE272393T1 (de) Rekonstruktion gereinigter membranproteine in vorgefertigten liposomen
CR8998A (es) PRODUCCION DE TNFR-Ig Y FUSION DE PROTEINA
ATE342962T1 (de) Zusammensetzungen und verfahren für verbesserte zellkultur
RU2010122052A (ru) Рекомбинантный фактор viii, обладающий повышенной стабильностью
AR063149A1 (es) Formulaciones a base de polipeptidos estables
NZ591292A (en) Improved cell composition and methods of making the same
CR8997A (es) Produccion de polipeptidos
NZ595495A (en) Cellulolytic enzymes, nucleic acids encoding them and methods for making and using them
MXPA03010433A (es) Metodos para produccion recombinante de peptidos antifusogenicos.
EP2536821A4 (en) IMPROVING THE EFFECT OF FE-S-BUNDLE REQUIRING PROTEINS
CO6231052A2 (es) Polipeptidos de factor vii modificados y usos de los mismos
DE69939327D1 (de) Funktionelle antagonisten von hedgehog-aktivität
DE69939330D1 (de) Wachstumsfaktor-homologe zvegf-3
Bab et al. Isolation of mitogenically active C‐terminal truncated pentapeptide of osteogenic growth peptide from human plasma and culture medium of murine osteoblastic cells
BRPI0514411B8 (pt) formulação, e, método de produzir uma formulação
AR012499A1 (es) Una secuencia quimerica de acido nucleico que codifica una proteina de fusion, un vector de expresion que comprende dicha secuencia quimerica, una celula huesped transformada que contiene dicho vector, la proteina de fusion obtenida y un metodo in vitro para la preparacion de un polipeptido recombin
Jankowski et al. Defining ‘full‐length’recombinant factor VIII: a comparative structural analysis
Collawn et al. Conditioned media from adipose-derived stromal cells accelerates healing in 3-dimensional skin cultures
ATE464320T1 (de) Ntb-a, ein oberflächenmolekül impliziert in der aktivität natürlicher killerzellen (nk)
ES2192199T3 (es) Ligandos de la familia eph biologicamente activos.
TR200200048T2 (tr) Otoproteolitik klevaj vasıtasıyla proteinlerin üretimi.

Legal Events

Date Code Title Description
FG Grant, registration